121 related articles for article (PubMed ID: 31310691)
1. Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.
Pereira TDSF; de Amorim LSD; Pereira NB; Vitório JG; Duarte-Andrade FF; Guimarães LM; Diniz MG; Gomes CC; Gomez RS
J Oral Pathol Med; 2019 Nov; 48(10):906-910. PubMed ID: 31310691
[TBL] [Abstract][Full Text] [Related]
2. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
3. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
4. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
5. GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation.
Lim YH; Bacchiocchi A; Qiu J; Straub R; Bruckner A; Bercovitch L; Narayan D; ; McNiff J; Ko C; Robinson-Bostom L; Antaya R; Halaban R; Choate KA
Am J Hum Genet; 2016 Aug; 99(2):443-50. PubMed ID: 27476652
[TBL] [Abstract][Full Text] [Related]
6. BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma.
Groesser L; Peterhof E; Evert M; Landthaler M; Berneburg M; Hafner C
J Invest Dermatol; 2016 Feb; 136(2):481-6. PubMed ID: 26802240
[TBL] [Abstract][Full Text] [Related]
7. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
8. GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system.
Gessi M; Hammes J; Lauriola L; Dörner E; Kirfel J; Kristiansen G; zur Muehlen A; Denkhaus D; Waha A; Pietsch T
Neuropathol Appl Neurobiol; 2013 Jun; 39(4):417-25. PubMed ID: 22758774
[TBL] [Abstract][Full Text] [Related]
9. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors.
Bologna-Molina R; Ogawa I; Mosqueda-Taylor A; Takata T; Sánchez-Romero C; Villarroel-Dorrego M; Takeda Y; Mikami T
Oral Dis; 2019 Mar; 25(2):481-487. PubMed ID: 30294831
[TBL] [Abstract][Full Text] [Related]
10. Activating
Shirazi F; Jones RJ; Singh RK; Zou J; Kuiatse I; Berkova Z; Wang H; Lee HC; Hong S; Dick L; Chattopadhyay N; Orlowski RZ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20004-20014. PubMed ID: 32747568
[No Abstract] [Full Text] [Related]
11. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Giménez N; Martínez-Trillos A; Montraveta A; Lopez-Guerra M; Rosich L; Nadeu F; Valero JG; Aymerich M; Magnano L; Rozman M; Matutes E; Delgado J; Baumann T; Gine E; González M; Alcoceba M; Terol MJ; Navarro B; Colado E; Payer AR; Puente XS; López-Otín C; Lopez-Guillermo A; Campo E; Colomer D; Villamor N
Haematologica; 2019 Mar; 104(3):576-586. PubMed ID: 30262568
[TBL] [Abstract][Full Text] [Related]
12. [Pyogenic granuloma with satellitosis].
Wagner G; Abbenseth R; Heine M; Rose C; Sachse MM
Hautarzt; 2020 Mar; 71(3):219-222. PubMed ID: 31659388
[TBL] [Abstract][Full Text] [Related]
13. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
14. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
15. Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer.
Grellety T; Gros A; Pedeutour F; Merlio JP; Duranton-Tanneur V; Italiano A; Soubeyran I
Virchows Arch; 2016 Oct; 469(4):459-64. PubMed ID: 27401719
[TBL] [Abstract][Full Text] [Related]
16. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
[TBL] [Abstract][Full Text] [Related]
17. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
18. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
Lokhandwala PM; Tseng LH; Rodriguez E; Zheng G; Pallavajjalla A; Gocke CD; Eshleman JR; Lin MT
BMC Cancer; 2019 Jul; 19(1):665. PubMed ID: 31277584
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
